Holen Sie sich die Stockscreener-App
9.44
0.74%
-0.07
Handel nachbörslich:
9.63
0.19
+2.01%
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
ZEVRA THERAPEUTICS Director John B Bode Acquires 5,000 Shares - TradingView
Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability - MSN
Is Zevra Therapeutics Inc. stock a falling knife or bargain buyWeekly Trading Summary & Capital Efficiency Focused Ideas - newsyoung.net
Institutional Investors in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Lost 22% Last Week but Have Reaped the Benefits of Longer-term Growth - 富途牛牛
Zevra Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised) - sharewise.com
Zevra signals continued MIPLYFFA momentum with 26% revenue growth and $150M PRV sale strengthening balance sheet - MSN
Zevra Therapeutics Q2 Earnings Top Revenue Estimates, Shares Up 40% YTD - AInvest
Can Zevra Therapeutics Inc. Outperform Peers After Recent PullbackWeekly Stock Recap & Risk Controlled Daily Trade Plans - sundaytimes.kr
How do insiders feel about Zevra Therapeutics Inc.Weekly Trading Summary & Accurate Buy Signal Notifications - thegnnews.com
Zevra Therapeutics’ SWOT analysis: stock soars on MIPLYFFA success, pipeline potential - Investing.com
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics at Canaccord Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - inkl
JMP Securities maintains Market Outperform on Zevra, lowers PT to $18. - AInvest
Price Channel Expanding on Zevra Therapeutics Inc.’s ChartShort Setup & Risk Controlled Swing Alerts - sundaytimes.kr
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2025 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics: Strong Buy Rating Amid U.S. Growth and EU Market Potential - TipRanks
Zevra Therapeutics price target lowered to $18 from $19 at Citizens JMP - TipRanks
Zevra Therapeutics shares fall 9.01% premarket despite Q2 profit and revenue growth. - AInvest
Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38 - MSN
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP - Investing.com Australia
Zevra Therapeutics stock price target lowered to $18 at Citizens JMP By Investing.com - Investing.com South Africa
Zevra Therapeutics shares fall 10.54% premarket despite Q2 revenue beating estimates. - AInvest
Zevra Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Zevra Revenue Jumps 486 Percent in Q2 - AOL.com
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: - GuruFocus
Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Zevra Therapeutics Reports Strong Q2 2025 Results - TipRanks
Zevra Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Zevra Therapeutics' Q2 2025 Earnings Call: Unraveling Contradictions in Patient Enrollment Strategies and Reimbursement Timelines - AInvest
Zevra Therapeutics (ZVRA) Reports Strong Q2 2025 Financials - GuruFocus
Transcript : Zevra Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Zevra Therapeutics Outpaces Earnings Estimates And Investor Optimism Builds - Finimize
Earnings call transcript: Zevra Therapeutics Q2 2025 misses EPS, revenue shines - Investing.com
ZEVRA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Zevra Q2 2025 net revenue at $25.9mln, arimoclomol approval sought in EU - AInvest
Zevra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Zevra Therapeutics Q2 Swing to Profits, Revenue Rises - MarketScreener
Zevra Therapeutics earnings missed by $2.25, revenue topped estimates - Investing.com Canada
Zevra Therapeutics falls as significant earnings miss overshadows revenue beat - Investing.com Nigeria
Zevra Therapeutics' Q2 Earnings Outperformance and Strategic Momentum in Rare Disease Therapies: A Deep Dive into Long-Term Investment Viability - AInvest
Zevra Therapeutics Q2 revenue beats estimates - MarketScreener
Zevra Therapeutics Q2 Non-GAAP EPS Misses by $1.44, Revenue Surpasses Expectations - AInvest
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):